CD274 and pachyonychia congenita: Besides, the fact that chemotherapy may promote immunogenic cell death in PC[6] and BRCA-mutant PC is frequently related to an increased tumor mutation burden and PD-1 expression,[7] forms the basis of an anti-PD-(L)1 agent combined with chemotherapy, as evidenced by a promising survival (mOS, 15 months) in a chemotherapy plus immunotherapy trial.[8] Tislelizumab, an anti-PD-1 monoclonal antibody, has made great progress in cancer treatment in recent decades.